

Revlimid[®] (lenalidomide) – New indications

- On May 28, 2019, [Celgene announced](#) the FDA approval of [Revlimid \(lenalidomide\)](#), in combination with a rituximab ([Rituxan[®]](#)) product for the treatment of adult patients with previously treated follicular lymphoma (FL) and marginal zone lymphoma (MZL).
- Revlimid is also approved for the treatment of adult patients with:
 - Multiple myeloma (MM), in combination with dexamethasone
 - MM, as maintenance following autologous hematopoietic stem cell transplantation
 - Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities
 - Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included [Velcade[®] \(bortezomib\)](#).
- The efficacy of Revlimid with rituximab in patients with relapsed or refractory FL and MZL was evaluated in the AUGMENT and MAGNIFY studies. AUGMENT was a double-blind study in which 358 patients with relapsed or refractory FL and MZL were randomized to Revlimid and rituximab or rituximab and placebo. Efficacy was established based on progression-free survival (PFS). MAGNIFY was an open-label study in which 232 patients with relapsed or refractory FL, MZL, or MCL received 12 induction cycles of Revlimid and rituximab.
 - In AUGMENT, the median PFS was 39.4 months in the Revlimid and rituximab group vs. 14.1 months in the rituximab and placebo group (hazard ratio: 0.46; 95% CI: 0.34, 0.62; $p < 0.0001$).
 - In addition, for the AUGMENT study, 77.5% (95% CI: 70.7, 83.4) of the Revlimid and rituximab group had an objective response vs. 53.3% (95% CI: 45.8, 60.8) of the rituximab and placebo group.
 - In the MAGNIFY study, the overall response was 59% (95% CI: 51, 66) for patients with FL. Median duration of response was not reached with a median follow-up time of 7.9 months (95% CI: 4.6, 9.2).
 - In the MAGNIFY study, the overall response was 51% (95% CI: 36, 66) for patients with MZL. Median duration of response was not reached with a median follow-up time of 11.5 months (95% CI: 8.0, 18.9).
- Revlimid carries a boxed warning for embryo-fetal toxicity, hematologic toxicity, and venous and arterial thromboembolism.
- The most common adverse reactions ($\geq 15\%$) with Revlimid use in MCL, FL, and MZL were neutropenia, thrombocytopenia, anemia, leukopenia, diarrhea, constipation, nausea, fatigue, pyrexia, cough, upper respiratory tract infection, and rash.
- The recommended starting dose of Revlimid for FL and MZL is 20 mg orally once daily on days 1 to 21 of repeated 28-day cycles for up to 12 cycles of treatment in combination with a rituximab-product.

- Refer to the Revlimid drug label for dosing recommendations for rituximab and for all other indications.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.